Years

Conference Details

Presenters

Speakers

Organizing Committee

Sponsors

Bayhelix China Healthcare Awards

Monday, November 12, 2018

6:00 PM to 9:00 PM

  • Welcome Reception
    Jing An Shangri-La hotel, Lifestyle Suite & Garden, 4th Floor

    Network with biotech CEOs and investors from China, Asia and the West. 

    Hosted by Pivotal China BioVenture, Nan Fung Life Sciences, BioCentury and BayHelix 

Tuesday, November 13, 2018
  • Innovation and Entrepreneurship at Home AND Abroad

8:00 AM to 8:50 AM

  • REGISTRATION AND BREAKFAST NETWORKING

8:50 AM to 9:00 AM

  • WELCOMING REMARKS
    • David Flores, President & CEO, BioCentury Inc. 
    • Victor Shi, Ph.D., Chairman, BayHelix, and Managing Partner, Serica Partners

9:00 AM to 9:50 AM

  • BLUE RIBBON PANEL: CHALLENGES ON THE ROAD TO GLOBALIZATION

    BayHelix convenes a special Blue Ribbon Panel to debate the mounting obstacles to globalization and their impact on China’s acceleration into the international healthcare ecosystem, its access to international talent and science, and its attractiveness as a destination for Western innovators and investors.

    • Kewen JIN, M.D., Managing Partner, Serica Partners (Session Chair & Moderator)
    • Tony Chen, Partner, Jones Day
    • Tao FU, President & Chief Operating Officer, Zai Lab 
    • Nisa Leung, Managing Partner, Qiming Ventures  
    • Bin LI, Ph.D., CEO, Ally Bridge LB Healthcare Fund 
    • Lianshan ZHANG, Ph.D., SVP and President, Global R&D, Jiangsu Hengrui Medicine Co. 

9:50 AM to 10:05 AM

  • MORNING NETWORKING BREAK

10:05 AM to 10:35 AM

  • BLUE RIBBON RAPPORTEUR SESSION: DOMESTIC BIOPHARMA

    In a Fireside Chat, the leader of the innovative domestic biopharma industry association responds to points raised during the China Summit’s Blue Ribbon Panel: Challenges on the Road to Globalization. 

    • Ruilin SONG, Executive President, PhIRDA (China Pharmaceutical Innovation and Research Development Association) 
    • Victor Shi, Ph.D., Chairman, BayHelix & Managing Partner, Serica Partners (Moderator)

10:05 AM to 11:45 PM

  • PRESENTING COMPANIES TRACK (SESSION 1)
    Ballroom 2

    10:05am-10:25am  Acepodia Inc.

    10:25am-10:45am  CBT Pharmaceuticals Inc.

    10:45am-11:05am  Insilico Medicine Inc.

    11:05am-11:25am  Hutchison China MediTech Ltd. (Chi-Med) (AIM/NASDAQ:HCM)

    11:25am-11:45am  Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) 

10:35 AM to 11:05 AM

  • BLUE RIBBON RAPPORTEUR SESSION: INTERNATIONAL BIOPHARMA

    International biopharma leaders respond to points raised during the China Summit’s Blue Ribbon Panel: Challenges on the Road to Globalization.  

    • David Flores, President & CEO, BioCentury Inc. (Session Chair & Moderator) 
    • Steve Bates, CEO, BioIndustry Association (BIA)  
    • Wei KANG, Managing Director, RDPAC (R&D-Based Pharmaceutical Association Committee) 
    • Hyunsang MUK, President & CEO, Korea Drug Development Fund (KDDF) 

11:05 AM to 11:50 PM

  • CHINA’S GLOBALIZATION CHALLENGE: INCUBATING BIOTECHS

    Every nation recognizes the importance of incubating life science start-ups. But only a few succeed. The challenges are even higher for China as it races to do so in a rapidly changing landscape. What must it do to create a robust incubator ecosystem that serves both domestic and international priorities simultaneously?  

    • Jimmy Wei, Ph.D., Managing Partner, Pivotal bioVenture Partners China (Session Chair & Moderator)  
    • Laura Benjamin, Ph.D., Founder & CEO, Oncologie Ltd. 
    • Da LIU, Managing Director, CR-CP Life Science Fund 
    • Tyrone Mao, Senior Director, Scientific Innovation, JLABS@Shanghai
    • Karoly Nikolich, Ph.D., CEO & Chairman, Alkahest Inc. 
    • Antoine Papiernik, Managing Partner, Sofinnova Partners 

11:50 AM to 1:15 PM

  • PLENARY: PRESENTING COMPANIES: GLOBAL BIOTECH TRACK 1 (SESSION 2) AND BOXED LUNCH
    Ballroom 1

    Hosted by Zai Lab Ltd., BioCentury and BayHelix 

    • Tao FU, President & Chief Operating Officer, Zai Lab Ltd. (emcee)

    11:55am-12:15pm  Zai Lab Ltd. (NASDAQ:ZLAB)

    12:15pm-12:35pm  Synaffix B.V.

    12:35pm-12:55pm  Arcus Biosciences Inc. (NYSE:RCUS)

    12:55pm-1:15pm  Xynomic Pharmaceuticals Inc.

1:20 PM to 2:10 PM

  • CHINA’S GLOBALIZATION CHALLENGE: DELIVERING RARE DISEASE SOLUTIONS AT HOME AND ABROAD?

    By issuing its first national rare disease list, China has opened the door to a huge untapped market. But the pathway from clinic to reimbursement still must be built. As the market evolves, what must domestic and Western innovators do to deliver hope to patients in China? And how can Chinese biotechs make their presence felt in the global rare disease landscape?  

    • James Xue, Ph.D., Chairman & CEO, Canbridge Life Sciences Ltd. (Session Chair & Moderator) 
    • Kevin Huang, Founder & President, Chinese Organization for Rare Disorders (CORD)
    • David Oxley, SVP, Business Development & Licensing, Mesoblast Ltd.
    • Gonghua PAN, Co-Founder, General Manager & Chief Operating Officer, Kira Pharmaceuticals 
    • Thaminda Ramanayake, Director, Business Development, BioMarin Pharmaceuticals 
    • Bin WANG, Ph.D., Head of Business Development, Boehringer Ingelheim Biopharmaceuticals China
    • Richard Yang, Founder & CEO, Reflection Biotechnologies

1:20 PM to 3:00 PM

  • PRESENTING COMPANIES: U.K. BIOTECH TRACK 1 (SESSION 3)
    Ballroom 2

    Hosted by the BioIndustry Association (BIA), BioCentury and BayHelix

    • Steve Bates, CEO, BIA (emcee)

    1:20pm-1:40pm  e-Therapeutics plc (LSE:ETX)  

    1:40pm-2:00pm  Crescendo Biologics Ltd. 

    2:00pm-2:20pm  F-star Biotechnology Ltd. 

    2:20pm-2:40pm  Scancell Holdings plc (LSE:SCLP; FSE:SCP) 

    2:40pm-3:00pm  Chain Biotechnology Ltd.

2:10 PM to 3:10 PM

  • CHINA’S GLOBALIZATION CHALLENGE: LEVERAGING ITS AI FUTURE

    China’s commitment to population health, artificial intelligence and machine learning give it the wherewithal to make great strides in applying technology to domestic healthcare. Can it also create digital health powerhouses on a global scale?   

    • Stanley Li, M.D., Founder, DXY (Session Chair) 
    • Andrea de Souza, Senior Director, Informatics, Eli Lilly and Company (Moderator) 
    • Chengming GU, M.D., VP, Medical Affairs, Greater China Region, Pfizer Inc.
    • Pek Lum, Ph.D., CEO & Founder, Auransa Inc.
    • Mao MAO, Ph.D., Founder & CEO, SeekIn Inc.
    • Tony Zhang, Founder & CEO, LinkDoc Technology (Beijing) Co. 
    • Alex Zhavoronkov, Ph.D., Co-Founder & CEO, Insilico Medicine Inc.

3:00 PM to 6:00 PM

  • PRESENTING COMPANIES: CHINA BIOTECH TRACK (SESSION 4)
    Ballroom 2

    Hosted by BeiGene Ltd., BioCentury and BayHelix 

    • Guillaume Vignon, Ph.D., SVP, Business Development, BeiGene Ltd. (emcee) 

    3:00pm-3:20pm  BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160)

    3:20pm-3:40pm  Laekna Therapeutics Shanghai Co. Ltd.

    3:40pm-4:00pm  Suzhou Ribo Life Science Co. Ltd.

    4:00pm-4:20pm  Yisheng Biopharma Co. Ltd.

    4:20pm-4:40pm  Abbisko Therapeutics Co. Ltd.

    4:40pm-5:00pm  Zhejiang Teruisi Pharmaceutical Inc.

    5:00pm-5:20pm  XW Laboratories Inc.

    5:20pm-5:40pm  PhageLux Inc.

    5:40pm-6:00pm  Elpiscience Biopharmaceuticals Co. Ltd. 

3:10 PM to 3:40 PM

  • AFTERNOON NETWORKING BREAK

3:40 PM to 4:30 PM

  • CHINA’S GLOBALIZATION CHALLENGE: BUILDING THE ACADEMIC-BIOTECH NEXUS

    Global innovation has been built on the shoulders of academic institutions and biotech companies, which continue to convert new science into breakthrough treatments. The challenge is to create a clear path for assets and IP from the university into the hands of entrepreneurs. What must China’s universities, innovators and investors do to build an internationally recognized innovation engine?  

    • Stella Xu, Ph.D., Managing Director, Quan Capital (Session Chair & Moderator) 
    • Deborah Chen, Ph.D., Head of Business Development & Licensing, Drug Discovery and Development, A*STAR, Singapore 
    • James Huang, Managing Partner, KPCB China, and Managing Partner, Panacea Venture 
    • Liming SHAO, Ph.D., Professor and Director, Shanghai Center for iDrug Discovery & Development, School of Pharmacy, Fudan University 
    • Litao ZHANG, Ph.D., VP, Leads Discovery & Optimization, Bristol-Myers Squibb Co. 
    • Nick Zhang, Ph.D., Chairman & CEO, Qiagen Suzhou Translational Medicine Co. Ltd. 

4:30 PM to 5:30 PM

  • WHITHER INNOVATION IN CHINA?

    In the China Summit’s 3rd Annual Heads of Research Roundtable, R&D heads and “scientist-CEOs” from China and Abroad analyze how far China has come and what it now must accomplish to meet international expectations. 

    • Steve Yang, Ph.D., EVP, Chief Business Officer, WuXi AppTec (Session Chair & Moderator) 
    • Ruth Gimeno, Ph.D., VP, Diabetes Research & Clinical Investigation, Eli Lilly and Co.  
    • Xiayang QIU, Ph.D., Founder, CEO & CSO, Regor Therapeutics Inc. 
    • Weiguo SU, Ph.D., Executive Director & CSO, Chi-Med (Hutchison China MediTech Ltd.)
    • Lai WANG, Ph.D., SVP, Head of China Development, BeiGene Ltd.
    • Yinxiang WANG, Ph.D., Founder & Chairman, Beijing Jacobio Pharma Co. Ltd.
    • Doug Williams, Ph.D., President & CEO, Codiak BioSciences 

6:00 PM to 10:00 PM

  • 5TH ANNIVERSARY GALA DINNER AND AFTER PARTY

    Celebrate the 5th anniversary of the BioCentury-BayHelix China Healthcare Summit with fellow delegates and Shanghai life sciences leaders at our Gala Dinner and After Party. 

    Hosted by C-Bridge Capital, H.C. Wainwright, BioCentury and BayHelix 

Wednesday, November 14, 2018
  • Theme: Managing for Domestic AND Global Impact

8:00 AM to 9:00 AM

  • PRESENTING COMPANIES: HONG KONG EXCHANGE SHOWCASE (SESSION 5) AND BREAKFAST NETWORKING
    Ballroom 1

    Hosted by: BioCentury and BayHelix

    8:00am-8:20am  GenScript Biotech Corp. (HKSE: 1548)

    8:20am-8:40am  Lee's Pharmaceutical Holdings Ltd. (HKSE:950)

    8:40am - 9:00am  Hua Medicine Ltd. (HKSE:2552)

9:00 AM to 9:05 AM

  • WELCOMING REMARKS

9:05 AM to 9:45 AM

  • KEYNOTE: THINKING BIG ABOUT CHINA’S HEALTHCARE ECOSYSTEM

    China's ambitious population health goals require brave initiatives, innovative partnerships and the skills of players from inside and outside the country. This opening keynote sets the stage for the day's discussion about how globally facing companies can work across borders and across technologies to create a healthy China.  

    • Leon Wang, EVP, International, AstraZeneca

9:45 AM to 10:45 AM

  • THE BRIDGE TO INNOVATION: LOOKING ACROSS TO 2025

    Insights Partner McKinsey & Co. delivers the key findings from its 5th exclusive China Healthcare Summit Report for conference delegates, reflecting on what must be done to complete the Bridge to Innovation and where it could lead by 2025.  

    • Fangning ZHANG, Partner, McKinsey & Co.

10:45 AM to 11:00 AM

  • MORNING NETWORKING BREAK

10:45 AM to 12:05 PM

  • PRESENTING COMPANIES: KOREA BIOTECH TRACK (SESSION 6)
    Ballroom 2

    Hosted by the Korea Drug Development Fund (KDDF), Kinhalo Ventures Korea, BioCentury and BayHelix

    • Tae-erk Kim, Chief Business Officer, KDDF (emcee)

    10:45am-11:05am  Daewoong Pharmaceutical Co. Ltd. (KSE:069620)

    11:05am-11:25am  Bio-Pharm Solutions

    11:25am-11:45am  Bioneer Corp. (KOSDAQ: 064550)

    11:45am-12:05pm  Wellmarker Bio Co. Ltd.

11:00 AM to 12:10 PM

  • VIEW FROM THE TOP: BIOPHARMA GM PERSPECTIVES

    In their 5th annual dialogue at the China Summit, general managers from the MNCs and China's emerging class of multinational biotechs share their formulas for building a profitable product mix as the market access landscape undergoes its next round of reforms. 

    • Aamir Malik, Senior Partner & Co-Leader, Global Pharmaceuticals and Medical Products Practice, McKinsey & Co. (Session Chair & Moderator) 
    • Rogier Janssens, General Manager, China, Merck Biopharma China 
    • Dirk Van Niekerk, General Manager, China, Boehringer Ingelheim 
    • Thomas Willemsen, Chairman, GSK China Investment Co. Ltd. 
    • Xiaobin WU, Ph.D., General Manager, China & President, BeiGene Ltd. 
    • Shirley Zhao, M.D., General Manager & President, China and Hong Kong, Bristol-Myers Squibb Co.

12:10 PM to 1:40 PM

  • 9TH ANNUAL BAYHELIX AWARDS LUNCH BANQUET

    BayHelix again celebrates outstanding individuals and companies for their achievements and contributions to China’s healthcare ecosystem in five categories: R&D Achievement of the Year; Deal of the Year; Commercial Achievement of the Year; Company of the Year; and Person of the Year. 

    • Victor Shi, Ph.D., Chairman, BayHelix, and Managing Partner, Serica Partners (emcee) 

1:40 PM to 2:30 PM

  • READY TO CROSS THE BRIDGE?

    As market pressures grow at home, Chinese pharmas are facing the imperative to globalize. Here’s how they plan to do it. Will they compete for deals with China’s internationally focused biotechs? And what does it mean for cross-border dealmakers from the West? 

    • Kevin Li, Ph.D., Co-Founder & Managing Partner, LYZZ Capital (Session Chair & Moderator) 
    • Darren Ji, Ph.D., CEO, Elpiscience Biopharmaceuticals Co. Ltd.
    • Peter Ji, Director, Business Development, Luoxin Pharmaceuticals
    • Ivor Royston, M.D., CEO, Viracta Therapeutics Inc. 
    • Joan Shen, M.D., Head of R&D, I-Mab Biopharma
    • Donald Wyatt, VP, Business Development, 3SBio Inc.

1:50 PM to 4:50 PM

  • PRESENTING COMPANIES GLOBAL BIOTECH TRACK 2 (SESSION 7)
    Ballroom 2

    Hosted by Zai Lab Ltd., BioCentury and BayHelix 

    • Tao FU, President & Chief Operating Officer, Zai Lab Ltd. (emcee)

    1:50pm-2:10pm  Eureka Therapeutics Inc.

    2:10pm-2:30pm  Hookipa Biotech AG

    2:30pm-2:50pm  Boston Pharmaceuticals Inc.

    2:50pm-3:10pm  Codiak BioSciences Inc.

    3:10pm-3:30pm  Refuge Biotechnologies Inc.

    3:30pm-3:50pm  F1 Oncology Inc.

    3:50pm-4:10pm  Life Length S.L.

    4:10pm-4:30pm  Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT)

    4:30pm-4:50pm  MiNA Therapeutics Ltd.

2:30 PM to 3:20 PM

  • CHINA’S GLOBALIZATION CHALLENGE: NEW MODALITIES AND ADVANCED MANUFACTURING

    In the race to lead in new therapeutic modalities like CAR T and other cell therapies, all roads run through manufacturing. But if global prowess in manufacturing is necessary, it is not sufficient. As China creates its beachhead in manufacturing, what more must it do to deliver these treatments to patients at home and abroad? 

    • Chelsea Zhang, Partner, Ping An Ventures (Session Chair & Moderator)
    • Jie D'Elia, Ph.D., Executive Director, Business Development, Bristol-Myers Squibb Co.
    • James Li, M.D., CEO, JW Therapeutics Inc. 
    • BG Rhee, CEO, SCM Life Sciences 
    • Peter Wang, VP, Manufacturing, CMAB
    • Shuyuan YAO, Ph.D., VP & Head, Advanced Therapy Unit, China, WuXi AppTec
    • Li ZHU, Ph.D., Chief Strategy Officer, GenScript Biotech Corp. and Nanjing Legend Biotech

3:20 PM to 3:40 PM

  • AFTERNOON NETWORKING BREAK

3:40 PM to 4:30 PM

  • CAPITAL MARKETS SHOWCASE: HOT MARKETS TODAY … WHAT ABOUT TOMORROW?

    2018 is chasing records for global financing for public and private biotechs, with IPO news dominating in both Hong Kong and the U.S. But what will be the story in 2019? And how should China’s biotechs be building a strategy for accessing the capital markets over the long-term, not just when the market is hot? 

    • Mengyu YU, Partner, Sidley Austin (Session Chair & Moderator) 
    • Ziyi CHEN, China Healthcare Research Analyst, Goldman Sachs 
    • Kenny Lam, Managing Director & Head of Healthcare Asia, Global Banking, HSBC 
    • George Lin, EVP & CFO, Hua Medicine 
    • Jonathan Wang, Ph.D., Co-founder & Senior Managing Director, OrbiMed Asia 
    • Jinzi WU, Ph.D., Founder, Chairman & CEO, Ascletis Pharma Inc.

4:30 PM to 5:00 PM

  • INTERNATIONAL PERSPECTIVES: VOICES FROM ABROAD

    In the Summit's capstone rapporteur session, biotech leaders from the U.S., Europe and Asia reflect on what they have learned about China's prospects for leadership at home and abroad in innovation and entrepreneurship. 

    • Simone Fishburn, Ph.D., Executive Editor, BioCentury (Session Chair & Moderator) 
    • Henk Joos, Director, Life Sciences, Healthcare & Agriculture, Agio Capital and Business Solutions
    • Brad Loncar, CEO, Loncar Investments
    • Kimberly Nearing, Managing Director & Head of Life Sciences, Cedrus Investments
    • Peter Pack, Ph.D., CEO, Crescendo Biologics Ltd.
    • Simranjit Singh, CEO, Asia, Middle East & Africa, Guardant Health Inc.

5:00 PM

  • CLOSING REMARKS